Genetix Names New CEO
The selection highlights Genetix’s plans to continue to grow its product lines for the clinical diagnostics market. In 2006, Genetix expanded its product line beyond research instruments and consumables to the diagnostics market by acquiring Applied Imaging (see IBO 11/30/06), which sells products for cancer pathology and cytogenetic.
New Milton, UK 7/31/08—Genetix has named Charles de Rohan CEO effective September 15. Mr. de Rohan is currently divisional vice president, Scientific Leadership and Global Accounts EMEA, for Abbott Laboratories’s Diagnostic Division. He will replace Mark Reid, who will serve as a nonexecutive director and strategic consultant for Genetix. “Charles’ extensive experience in the clinical diagnostic field will help us further expand and fully exploit our new product line opportunities within this exciting, fast-growing market,” stated Mr. Reid. In addition, Genetix’s Chairman of the Board John Morgan will step down to become a nonexecutive chairman effective August 4. He will be replaced by Dr. James Hill, currently a nonexecutive chairman.
